Lateral Flow Assays (LFAs) have become the foundation of point-of-care (POC) diagnostics, valued for their user-friendly format, cost-effectiveness, and rapid turnaround time. However, despite their widespread success, most notably in pregnancy testing and infectious disease monitoring, conventional colorimetric LFAs often suffer from insufficient sensitivity, limiting their utility for the early-stage detection of low-abundance biomarkers. This review provides a critical analysis of recent strategies have been developed to improve the sensitivity of these assays. Enhancement strategies are systematically classified into six distinct domains: (i) flow modulation techniques that optimise reaction kinetics; (ii) sample preconcentration methods; (iii) advanced signal transduction reporters beyond traditional gold nanoparticles; (iv) chemical signal amplification including nanozyme and enzymatic catalysis; (v) structural strategies for maximising label accumulation; and (vi) the engineering of aptamers as programmable recognition elements. Special emphasis is placed on ”reagent-free” and ”equipment-free” innovations that boost performance without compromising the inherent simplicity of the device. Finally, the emerging transition from passive biological selection to active molecular engineering is discussed, outlining the future trajectory of ultra-sensitive next-generation LFAs.